EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Acromegaly screening in patients with hyperprolactinemia and pituitary adenoma

Yu A Ukhanova, I A Ilovayskaya

Problems of Endocrinology · 2023

DOI: 10.14341/probl13344 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Problems of Endocrinology, 2023. Verfasst von Yu A Ukhanova und 1 weiteren Autor:innen. Beteiligte Einrichtung: Moscow Regional Research and Clinical Institute. Hauptthemen laut MEDLINE: Hyperprolactinemia, Acromegaly, Pituitary Neoplasms, Insulin-Like Growth Factor I. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND : Hyperprolactinemia accompanies growth hormone hypersecretion in approximately 25-39% of cases. There is a recommendation to determine the level of prolactin in clinical guidelines for diagnosis and treatment of acromegaly. However, there is no understanding of the necessity to investigate the IGF-1 level in patients with hyperprolactinemia and a pituitary adenoma. AIM : Determining the proportion of patients with hyperprolactinemia and pituitary adenoma, who were examined for IGF-1 levels, and identifying the proportion of patients with acromegaly among this cohort. MATERIALS AND METHODS : Between December 2019 and December 2022 a single-center observational single-stage single-sample uncontrolled study was conducted. At the first stage of the study, the proportion of patients with pituitary adenoma and hyperprolactinemia with studied IGF-1 levels was determined, according to medical records. At the second stage of the study, patients without known indicators of IGF-1 were determined. The concentration of growth hormone was studied during the oral glucose load in the case of increased IGF-1 levels. RESULTS : At the first stage, 105 patients were included in the study. The level of IGF-1 was determined in 41/105 (39%) cases. There were 22/41 (53.7%) cases in the subgroup with pituitary incidentalomas and 19/64 (29.7%) cases in the subgroup with hyperprolactinemia among them. At the second stage, the IGF-1 level was additionally determined in 53 patients with hyperprolactinemia and pituitary adenoma (total 94 patients). The level of IGF-1 was elevated in 11/94 patients, further acromegaly was confirmed in 3/94 patients (3.2%). CONCLUSION : In real clinical practice the level of IGF-1 is studied only in 39% of cases in patients with pituitary adenoma and hyperprolactinemia. The disease was detected in 3 cases (3.2%) out of 94 people with hyperprolactinemia and pituitary adenoma without clinical manifestations of acromegaly. We consider the study of IGF-1 levels justified as a screening for acromegaly in patients with hyperprolactinemia and pituitary adenoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperprolactinemiaAcromegalyPituitary NeoplasmsInsulin-Like Growth Factor IHumansFemaleMaleAdultMiddle AgedAdenomaHuman Growth Hormone

Substanzen

Insulin-Like Growth Factor IIGF1 protein, humanHuman Growth Hormone

Autor:innen und Institutionen

  • Moscow Regional Research and Clinical Institute.

Zitieren

APA

Ukhanova, Y. A., & Ilovayskaya, I. A. (2023). Acromegaly screening in patients with hyperprolactinemia and pituitary adenoma. Problems of Endocrinology. https://doi.org/10.14341/probl13344

Vancouver

Ukhanova YA, Ilovayskaya IA. Acromegaly screening in patients with hyperprolactinemia and pituitary adenoma. Problems of Endocrinology. 2023. doi:10.14341/probl13344

BibTeX
@article{Ukhanova2023,
  author = {Ukhanova, Yu A and Ilovayskaya, I A},
  title = {Acromegaly screening in patients with hyperprolactinemia and pituitary adenoma},
  journal = {Problems of Endocrinology},
  year = {2023},
  doi = {10.14341/probl13344}
}
Kostenlos starten →